点击上面“蓝字”关注我们!本文来源于潮药Bar;如果喜欢,欢迎在文末处点个“在看”,感谢您的支持!笔者其实不喜欢去写关于公司负面的文章,但有些公司实在是泡沫让人觉得非常离谱,不得不写了。昨天在创新药普遍大跌的情况下,药捷安康却逆势大涨,市值达到了431亿元人民币。药捷安康的首发适应症胆管癌,用于三线及以后治疗,并不是很大的适应症,况且它的首发适应症是FGFR突变的后线治疗的胆管癌患者,关于这个我在...
Source Link点击上面“蓝字”关注我们!本文来源于潮药Bar;如果喜欢,欢迎在文末处点个“在看”,感谢您的支持!笔者其实不喜欢去写关于公司负面的文章,但有些公司实在是泡沫让人觉得非常离谱,不得不写了。昨天在创新药普遍大跌的情况下,药捷安康却逆势大涨,市值达到了431亿元人民币。药捷安康的首发适应症胆管癌,用于三线及以后治疗,并不是很大的适应症,况且它的首发适应症是FGFR突变的后线治疗的胆管癌患者,关于这个我在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.